We report two cases of patients with malignant lymphoma who presented with early onset of hemophagocytic syndrome after nonmyeloablative allogeneic peripheral blood stem cell transplantation. Fever and skin eruption developed early after transplantation, and neurological symptoms preceded cytopenia and worsened progressively. Activated macrophages with hemophagocytosis were found in bone marrow of the two patients at day 15 and 56, respectively. The fact that no obvious infectious agents associated with hemophagocytic syndrome were detected, and that serum soluble interleukin-2 receptor concentrations were elevated in the early phase after transplantation, reflecting the activation of donor-derived T cells, suggests that this complication resulted from an alloimmune response.
Recently, new approaches to allogeneic hematopoietic stem cell transplantation with nonmyeloablative conditioning have been used, mainly for patients who cannot tolerate high-dose therapy because of age or various medical conditions. [1] [2] [3] In general, because of the reduced regimenrelated toxicity, this procedure is thought to be safer than conventional myeloablative hematopoietic stem cell transplantation. However, life-threatening severe graft-versushost disease (GVHD) has often been observed with this procedure. The alloimmune response induced by donorderived cells is sometimes too potent to be brought under control. We report two cases of early onset of hemophagocytic syndrome (HPS) which might be related to an alloimmune response after nonmyeloablative hematopoietic stem cell transplantation (NST) conditioned with low-dose total body irradiation (TBI). 
Case reports

Case 1
A 39-year-old man was referred to our hospital because of multiple swellings of bilateral inguinal, para-aortic and retroperitoneal lymph nodes. He was diagnosed as follicular lymphoma after biopsy of the right inguinal lymph node. In spite of many courses of chemotherapy including CHOP (cyclophosphamide, adriamycin, vincristine and prednisolone) and CVP (cyclophosphamide, vincristine and prednisolone), administered about once a month for 6 years, only a minor response was obtained. The tumors gradually increased in size. Then, at the age of 45, the patient underwent allogeneic peripheral blood stem cell transplantation from his HLA-A, B, C and DR locus-matched father. Because of cardiac dysfunction, nonmyeloablative conditioning with low-dose TBI (2 Gy) was given. The numbers of infused CD34 + cells and CD3 + cells were 1.75 × 10 6 /kg and 1.86 × 10 8 /kg, respectively. Mycophenolate mofetil (MMF) (30 mg/kg p.o. in divided doses, from day 0) and cyclosporine (CsA) (3 mg/kg/day continuous infusion, from day −1) were used for prophylaxis of GVHD.
1 Serum levels of CsA were targeted to 400 ng/ml. On day 6 fever developed, then a skin eruption (macropapular exanthema), and diarrhea developed on day 8. However, biopsy specimens showed no apparent evidence of GVHD. Serum soluble interleukin-2 receptor (SIL-2R) concentration increased from 2140 to 10 100 U/ml on day 12. The patient suffered from severe headache on day 10, and manifested tremor and disorientation on day 13. Results for assays for genomic DNA of herpes simplex virus, varicello-zoster virus, Epstein-Barr virus, cytomegalovirus, human herpes virus-6, adenovirus, Candida, Aspergillus and tuberculosis in the cerebro-spinal fluid and serum were all negative. The patient could not take MMF on day 14, so dexamethasone (DEX) was used instead. However, disturbance of consciousness and pancytopenia progressed. On day 15, bone marrow aspiration revealed an increase in the proportion of activated macrophages (5.2%). The serum concentration of ferritin was high (1405.1 ng/ml), and activated macrophages were also found in the peripheral blood ( Figure 1a ) and cerebro-spinal fluid ( Figure 1b) . In spite of methyl-prednisolone (m-PSL) pulse therapy and administration of etoposide, bone marrow aspiration on day 33 showed marked hypocellularity and a further increase in the proportion of activated macrophages (57%) (Figure 1c ). The patient died on day 39 due to multiple organ failure (Figure 2 ). Complete chimerism in peripheral blood was confirmed at day 28 with PCR-based assays in which polymorphic short tandem repeat markers were analyzed. 
Case 2
A 50-year-old woman, diagnosed as diffuse large B cell lymphoma extending from the anterior mediastinum to the thyroid gland, was admitted because of relapse 5 months after autologous peripheral blood stem cell transplantation with conditioning by ICE (ifosfamide, carboplatin and etoposide). She achieved partial remission after 50 Gy of radiation therapy. However, the tumors increased in size. After two courses of salvage therapy to reduce the size of the tumors, the patient was given low-dose TBI (2 Gy) followed by infusion of granulocyte colony-stimulating factor (G-CSF) mobilized allogeneic peripheral blood stem cells from her HLA-DR one locus-mismatched sibling donor. MMF and CsA were used as prophylaxis of GVHD. The numbers of infused CD34 + cells and CD3 + cells were 4.16 × 10 6 /kg and 2.90 × 10 8 /kg, respectively. On day 3 fever developed and a skin eruption (macropapular exanthema) developed on day 19. SIL-2R increased from 332 to 6780 U/ml on day 7. The patient manifested a tremor on day 17 and lost consciousness with an attack of tonic convulsion on day 27. As with case 1, results of assays for genomic DNA of several infectious agents in the cerebrospinal fluid and serum were all negative. Initially, neurological complications caused by CsA were suspected, so CsA was discontinued and m-PSL was administered. However, the disturbance of consciousness never resolved and pancytopenia progressed. On day 56 bone marrow aspiration revealed 6.0% of activated macrophages with hemophagocytosis. M-PSL pulse therapy was not effective and the patient died from gastro-intestinal bleeding on day 67.
At autopsy, there were no residual masses or evidence of infection. The patient exhibited complete chimerism in peripheral blood at day 28 and 56.
Discussion
Hemophagocytic syndrome (HPS) is characterized by proliferation of activated macrophages under conditions such as infection, lymphoma or autoimmune disease. The diagnosis of HPS was made according to the following criteria: 5 (1) sustained fever over 7 days, (2) progressive cytopenia, and (3) the presence of more than 3% mature macrophages in bone marrow. Marked and acute elevation of serum concentrations of ferritin and SIL-2 R supported the diagnosis of HPS.
The present two cases of HPS after NST had some features in common as follows: (1) early onset of fever and skin eruption with elevation of serum concentrations of SIL-2R; (2) no obvious infectious agents were detected; (3) neurological symptoms, which are hard to distinguish from symptoms of CsA-induced encephalopathy, preceded the cytopenia and worsened progressively despite discontinuation of CsA. Thrombotic microangiopathy and cerebral vascular disease are important in the differential diagnosis. However, in both the present cases, no red cell fragmentation was found in peripheral blood smears and magnetic resonance imaging (MRI) of the brain showed no definite findings. We concluded that the present patients' symptoms indicated HPS. It has been reported that primary hemophagocytic lymphohistiocytosis (HLH) sometimes affects the central nervous system. 6 This can result in misdiagnosis because neurologic symptoms often precede systemic ones.
There have been several reports of HPS after hematopoietic stem cell transplantation, involving not only allogeneic but also autologous transplantation. Many of these reports have shown an association with viral infections, such as adenovirus 7 and cytomegalovirus, 8, 9 but there has been at least one case report in which a causative viral infection was not documented 10 as in our cases. However, NST is an intensely immunosuppressive procedure, and the possibility that other infectious agents might have caused this complication cannot be ignored. Another possibility is that a severe alloimmune response resulted in the HPS. The donors were not HLA-identical siblings; one was an A, B and DR locus identical father and the other was a one DR locus mismatched sibling. These differences might have caused the severe alloimmune response. Furthermore, these two patients had been receiving large amounts of anticancer drugs or radiation therapy for a long time before NST. This long history of prior therapy promoted the early engraftment of donor cells. On the other hand, damage to host tissue during such a long period of chemotherapy may have activated these tissues and caused secretion of Bone Marrow Transplantation inflammatory cytokines more readily after infusion of the allografts. Dysregulated release of cytokines might be related to activation of donor-derived T cells via enhancement of expression of major histocompatibility complex (MHC) antigens on host cells. Hypercytokinemia associated with T cell and macrophage activation plays an important role in the occurrence and progress of HPS. 11 The number of monocytes preserved compared to the situation with myeloablative regimens, might be related to HPS. It is unclear whether the incidence of this rare complication is higher with nonmyeloablative conditioning than with conventional myeloablative conditioning. However, we believe that great care should be taken when using NST to treat older patients with a long history of chemo-radiotherapy.
